2006
DOI: 10.1016/j.biomaterials.2005.08.030
|View full text |Cite
|
Sign up to set email alerts
|

Long-term and zero-order release of basic fibroblast growth factor from heparin-conjugated poly(l-lactide-co-glycolide) nanospheres and fibrin gel

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

3
120
0

Year Published

2008
2008
2023
2023

Publication Types

Select...
6
3
1

Relationship

0
10

Authors

Journals

citations
Cited by 164 publications
(123 citation statements)
references
References 25 publications
3
120
0
Order By: Relevance
“…A study in rabbits using MSCs, elastic block copolymer scaffolds and TGF-β 3 , showed that chondroitin sulphate-bound TGF-β 3 had a slower release profile than TGF-β directly incorporated into the scaffold (Park et al, 2010). Similar results have been achieved by binding TGF-β 3 (Park et al, 2008) or bFGF (Jeon et al, 2006) to heparin. Loaded structures.…”
Section: Direct Attachment or Incorporationmentioning
confidence: 80%
“…A study in rabbits using MSCs, elastic block copolymer scaffolds and TGF-β 3 , showed that chondroitin sulphate-bound TGF-β 3 had a slower release profile than TGF-β directly incorporated into the scaffold (Park et al, 2010). Similar results have been achieved by binding TGF-β 3 (Park et al, 2008) or bFGF (Jeon et al, 2006) to heparin. Loaded structures.…”
Section: Direct Attachment or Incorporationmentioning
confidence: 80%
“…For example, heparin-conjugated PLGA nanospheres (HCPNs), trapped in cross-linked fibrin gel, were developed for long-term and zero-order delivery of bFGF. Heparin was immobilized on PLGA nanospheres via a coupling reaction in the presence of EDC and the bFGF was physically bonded to heparin [202]. The release kinetics of bFGF from HCPNs suspended in fibrin gel was of zero order, sustained for three weeks with no initial burst effect.…”
Section: Interaction With Glycosaminoglycansmentioning
confidence: 99%
“…21 For example, bone healing time varies from days to weeks to months, depending on the nature of bone defects. 22,23 Extensive efforts have been focused on reducing the initial burst release of drug carriers by controlling formulation parameters of the carriers such as molecular weight, hydrophilicity, as well as drug loading amount. 21 Recently, our laboratory has developed a biodegradable hydrogel of PEG sebacic acid diacrylate (PEGSDA), based on PEG and sebacic acid macromer terminated with acrylate groups.…”
Section: Introductionmentioning
confidence: 99%